Picture this: You're a heart disease patient fresh out of major surgery, and your body is struggling to bounce back. Could the simple act of getting a blood transfusion sooner rather than later actually shield your heart from failure or irregular rhythms? A groundbreaking study on U.S. military veterans suggests it might – but not without stirring some heated debates in the medical world. Dive in to uncover the surprising details that could change how we think about post-op care.
Research Highlights:
- Opting for a blood transfusion earlier after major surgery – specifically when hemoglobin dips below 10 grams per deciliter instead of waiting until it falls below 7 grams per deciliter – had no impact on the likelihood of grave complications like death, heart attack, the need for cardiac procedures, kidney failure, or stroke.
- Yet, the moment you choose for that blood transfusion could link to a decreased chance of developing irregular heartbeat or heart failure in individuals battling heart disease, as revealed by this fresh investigation into U.S. military veterans.
- Important update: This study is being released in full today as a complete article in the esteemed, peer-reviewed journal JAMA.
This information is under embargo until 3:57 p.m. Central Time or 4:57 p.m. Eastern Time on Saturday, November 8, 2025.
NEW ORLEANS, Nov. 8, 2025 — Administering a blood transfusion at a higher hemoglobin level following significant general or vascular surgery in patients with heart disease correlated with a reduced risk of certain complications, though not the most critical ones, based on a preliminary late-breaking science presentation delivered today at the American Heart Association’s Scientific Sessions 2025 (https://professional.heart.org/en/meetings/scientific-sessions). This conference, running from November 7-10 in New Orleans, stands as a top-tier international platform for exchanging the newest scientific discoveries, research findings, and updates on evidence-based clinical practices in cardiovascular health.
The Transfusion Trigger after Operations in High Cardiac Risk Patients (TOP) trial explored whether providing blood transfusions sooner – when hemoglobin levels drop below 10 g/dL post-surgery – could better ward off complications in heart patients compared to a strategy that delays transfusions until hemoglobin plummets to below 7 g/dL. For those new to this, hemoglobin is a crucial protein in red blood cells responsible for ferrying oxygen from your lungs to every part of your body. Think of it as the delivery truck keeping your tissues fueled.
In this analysis involving over 1,400 military veterans undergoing major general or vascular surgery, hemoglobin was checked right after the operation and again following each transfusion to decide if more were needed, continuing until discharge or up to 30 days post-surgery, whichever happened first.
The study pitted the overall incidence of major complications – including death, heart attack, kidney failure, the requirement for heart procedures, or stroke – against less devastating but still concerning issues like pneumonia, sepsis, wound infections, new irregular heartbeats (also known as arrhythmias – when your heart's rhythm goes off-kilter, potentially causing fluttering or skipped beats), sudden cardiac arrest (a complete stoppage of heart function), or heart failure (when the heart can't pump blood effectively, leading to fatigue, swelling, and shortness of breath). All outcomes were tracked 90 days after surgery.
“When surgery leads to heavy blood loss or anemia, a transfusion might become essential. For those with heart disease, the added stress from blood loss heightens complication risks, making the transfusion's timing absolutely key,” shared lead author Panos Kougias, M.D., M.Sc., who heads the surgery department at SUNY Downstate Health Sciences University in Brooklyn, New York. “Traditionally, most patients follow a guideline of holding off until hemoglobin is quite low before transfusing.”
“And this is the part most people miss – our results indicate that ongoing blood loss in patients with severe heart conditions doesn't ramp up the danger of critical issues like death, heart attack, kidney failure, needing heart interventions, or stroke. Instead, it could overburden the heart more than the fluid from a transfusion, sparking problems such as heart failure and arrhythmias,” Kougias continued. “An earlier transfusion approach might safeguard the heart from blood loss impacts. It's akin to maintaining your car's gas tank above half-full, versus refueling only when the low-fuel warning lights up.”
But here's where it gets controversial – the findings challenge long-held beliefs about transfusions potentially straining the heart with excess volume, turning the tables on when to act.
The breakdown revealed:
- Rates of severe complications – encompassing death, heart attack, kidney failure, the need for cardiac procedures, or stroke – were comparable between groups receiving earlier or later transfusions: 9.1% for the early (liberal) transfusion cohort versus 10.1% for the later (restrictive) group.
- Irregular heart rhythms and heart failure struck 5.9% of those in the early (liberal) transfusion group, contrasted with 9.9% in the later (restrictive) group, indicating a notable 41% drop in risk for the earlier transfusion recipients.
“We were astonished that the restrictive transfusion method – which means giving blood only when hemoglobin drops below 7 g/dL, effectively less blood overall – tied to a higher incidence of heart failure,” Kougias remarked. “Conventionally, experts worried that extra blood might overburden the heart and exacerbate failure. But our data points to prolonged anemia possibly taxing the heart more than transfusion volume, resulting in conditions like heart failure and arrhythmias. Since this was a secondary outcome, more studies are essential to validate it.
“This underscores that a universal transfusion approach might not suit everyone,” he added. “For certain patients, delaying remains safe. Yet for those with advanced heart disease facing major surgery, an earlier transfusion appears to help avert significant heart troubles, excluding heart attacks.”
The study does have constraints: The majority of participants were men, so outcomes might differ for women. Healthcare providers knew the transfusion strategy assigned to each patient, potentially influencing care. Plus, severe complications were fewer than anticipated, possibly masking subtle differences.
Study details, background, and design:
- The TOP trial encompassed 1,424 U.S. military veterans treated at 16 Veterans Affairs Medical Centers across the nation, recruited from February 2018 through March 2023.
- Average participant age was 70; 98% identified as men; and racially, 75% described themselves as white, 19% as Black, and 4% as Hispanic or Latino.
- Thresholds differed: Hemoglobin under 10 g/dL triggered the early or liberal approach, while under 7 g/dL prompted the later or restrictive one.
- Hemoglobin was monitored post-surgery and after every transfusion.
- Follow-up lasted 90 days post-operation.
Co-authors and disclosures appear in the abstract. Funding came from the Veterans Affairs Office of Research and Development.
Statements and conclusions from studies presented at the American Heart Association’s scientific meetings represent only the authors’ views and do not reflect the Association’s official stance or policies. The Association offers no assurances on their precision or dependability. Abstracts at these meetings aren't peer-reviewed; instead, they're selected by independent panels for their potential to enrich the range of scientific topics and perspectives. Results remain preliminary until a full paper appears in a peer-reviewed journal.
The Association derives over 85% of its funding from non-corporate sources, such as individual donations, foundations, estates, investment returns, and sales of educational materials. Companies, including those in pharmaceuticals and devices, also contribute, but strict rules ensure no influence on science or policy. Full financial details are here (https://www.heart.org/en/about-us/aha-financial-information).
Additional Resources:
- Visual and audio materials are accessible in the right column of the release link (https://newsroom.heart.org/news/earlier-blood-transfusion-may-reduce-heart-failure-arrhythmia-in-adults-with-heart-disease?preview=7de24da48f0b681040e29c54daa59e0f).
- Link to the abstract (https://eppro02.ativ.me/appinfo.php?page=Session&project=AHA25&id=4386390&server=eppro02.ativ.me); and the American Heart Association’s Scientific Sessions 2025 Online Program Planner (https://eppro02.ativ.me/web/planner.php?id=AHA25)
- Related American Heart Association press release: Red blood cell transfusions may improve outcomes in heart attack patients with anemia (https://newsroom.heart.org/news/red-blood-cell-transfusions-may-improve-outcomes-in-heart-attack-patients-with-anemia) (Nov. 2023)
- About Scientific Sessions 2025 (https://professional.heart.org/en/meetings/scientific-sessions)
- For more updates from the American Heart Association’s Scientific Sessions 2025, follow us on X @HeartNews (https://x.com/HeartNews), #AHA25
About the American Heart Association
The American Heart Association is an unwavering champion for longer, healthier lives everywhere. Committed to fair health across all communities, it has served as a trusted fountain of wellness info for over a century. Backed by more than 35 million volunteers worldwide, we drive innovative research, push for public health advocacy, and deliver vital tools to rescue and enhance lives impacted by heart disease and stroke. Through scientific leaps, policy shifts, and care improvements, we relentlessly pursue better health and life transformations daily. Join the conversation at heart.org (http://www.heart.org/en), Facebook (http://facebook.com/AmericanHeart), X (http://x.com/American_Heart), or call 1-800-AHA-USA1.
For Media Inquiries and American Heart Association Expert Perspective: 214-706-1173
American Heart Association Communications & Media Relations in Dallas: ahacommunications@heart.org
Bridgette McNeill: bridgette.mcneill@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org (http://www.heart.org/) and stroke.org (http://www.stroke.org/)
What do you think – does this study flip the script on transfusion timing for heart patients, or are we overlooking potential risks of earlier interventions? Is prolonged anemia truly more harmful than transfusion overload in high-risk cases? Share your thoughts in the comments below; we'd love to hear agreements, disagreements, or even personal experiences that might shed more light on this intriguing topic!
